Basit öğe kaydını göster

dc.contributor.authorKalemci, S.
dc.contributor.authorMicili, S. Cilaker
dc.contributor.authorAcar, T.
dc.contributor.authorSenol, T.
dc.contributor.authorDirican, N.
dc.contributor.authorOmeroglu, G.
dc.contributor.authorYilmaz, O.
dc.date.accessioned2020-11-20T16:20:33Z
dc.date.available2020-11-20T16:20:33Z
dc.date.issued2013
dc.identifier.issn0009-9074
dc.identifier.issn1972-6007
dc.identifier.urihttps://doi.org/10.7417/CT.2013.1559
dc.identifier.urihttps://hdl.handle.net/20.500.12809/3919
dc.descriptionkamaci, gonca/0000-0002-7156-4116; Bagriyanik, Husnu/0000-0003-4064-7637; Bagriyanik, Alper/0000-0003-2143-007Xen_US
dc.descriptionWOS: 000323910300003en_US
dc.descriptionPubMed ID: 23868629en_US
dc.description.abstractBackground. Thymoquinone (TQ), the main active constituent of the volatile oil extracted from Nigella sativa's seeds, is used for the treatment of inflammatory diseases and exhibits a variety of pharmacological effects. Methods. Twenty-eight BALB/c female mice were divided into four groups: I (sham-operated control group), II, III, and IV. All groups except for the sham-operated group were sensitized and challenged with ovalbumin. The sham-operated group received nebulized saline in challenge period. Mice in groups III and IV were administered TQ at a dose of 3 mg/kg and dexamethasone 1 mg/kg, respectively, intraperitoneally once a day for the final 5 days of the challenge period. Animals were sacrificed 24 h after the last drug administration and the airway samples were evaluated histologically by light microscopy. Results. All histological parameters in Group III, similar to Group IV, were improved when compared to Group II. All variables except numbers of goblet cells were found to be significantly better in Group III and Group IV compared to Group II. Conclusions. In our study, we demonstrated that TQ administration alleviates the pathological changes of chronic asthma. TQ might be a promising therapy for asthma in the future.en_US
dc.item-language.isoengen_US
dc.publisherSoc Editrice Univen_US
dc.item-rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnti-Inflammatoryen_US
dc.subjectChronic Asthmaen_US
dc.subjectThymoquinoneen_US
dc.subjectMouseen_US
dc.subjectTreatmenten_US
dc.titleEffectiveness of thymoquinone in the treatment of experimental asthmaen_US
dc.item-typearticleen_US
dc.contributor.departmenten_US
dc.contributor.departmentTemp[Kalemci, S.] Mugla Univ, Fac Med, Dept Chest Dis, Mugla, Turkey -- [Micili, S. Cilaker; Bagriyanik, A.] Dokuz Eylul Univ, Fac Med, Dept Histol, Izmir, Turkey -- [Acar, T.] Sifa Univ, Fac Med, Dept Anat, Izmir, Turkey -- [Senol, T.] OSM Ortadogu Hosp, Sanliurfa, Turkey -- [Dirican, N.] Suat Seren Chest Dis & Surg Training & Res Hosp, Dept Chest Dis, Izmir, Turkey -- [Omeroglu, G.] Dokuz Eylul Univ, Fac Med, Dept Chest Dis, Izmir, Turkeyen_US
dc.identifier.doi10.7417/CT.2013.1559
dc.identifier.volume164en_US
dc.identifier.issue3en_US
dc.identifier.startpageE155en_US
dc.identifier.endpageE158en_US
dc.relation.journalClinica Terapeuticaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster